Security007903BD8 / Advanced Micro Devices, Inc. Bond 2.125%, 9/1/2026 (007903BD8)
President & CEOSu Lisa T
IndustrySemiconductors and Related Devices
Institutional Owners62
Institutional Shares46,400,155 - 4.76%
Common Stock Shares Outstanding975,000,000 shares (as of 2018-06-30)
Institutional Value$ 42,591,962,000 USD
Related AMD / Advanced Micro Devices, Inc.
007903BC0 / Advanced Micro Devices, Inc. Bond
007903AL1 / Advanced Micro Devices, Inc. Bond 6%, 5/1/2015
007903AU1 / Advanced Micro Devices Inc Senior Notes 7.75% 08/01/2020
007903AR8 / Advanced Micro Devices Inc Senior Notes 8.125% 12/15/2017

Institutional Bond Ownership and Shareholders()

007903BD8 / Advanced Micro Devices, Inc. Bond 2.125%, 9/1/2026 Institutional Ownership

Advanced Micro Devices, Inc. Bond 2.125%, 9/1/2026 (007903BD8) has 62 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 46,400,155 shares. Largest shareholders include State Street Corp, Thrivent Financial For Lutherans, Elliott Management Corporation, Mohican Financial Management, LLC, Bank of New York Mellon Corp, Jane Street Group, Llc, North Star Investment Management Corp., Front Row Advisors Llc, and Natixis Asset Management.
Advanced Micro Devices, Inc. Bond 2.125%, 9/1/2026 (007903BD8) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR Polar Asset Management Partners Inc. 7,334 19,906 171.42
2018-07-17 13F-HR Calamos Advisors LLC 42,992 58,661 36.45
2018-08-14 13F-HR Natixis Asset Management 155 155 0.00 228 309 35.53
2017-02-10 13F-HR BlackRock Fund Advisors 109 184 68.81
2018-08-10 13F-HR FMR LLC / Fidelity 16,850 17,778 5.51
2018-08-13 13F-HR LAZARD ASSET MANAGEMENT LLC 3,673 9,938 170.57
2018-02-14 13F-HR Man Investments (CH) AG 436 300 -31.19
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 9,953 5,687 -42.86
2018-08-14 13F-HR ADVENT CAPITAL MANAGEMENT /DE/ 17,869 19,207 7.49
2018-07-23 13F-HR Mohican Financial Management, LLC 1,048,000 1,148,000 9.54 1,478 2,286 54.67
2018-08-13 13F-HR Allianz Asset Management AG 62,013 103,257 66.51
2018-08-14 13F-HR QVT Financial LP 29,370 20,650 -29.69
2018-08-01 13F-HR BNP Paribas Investment Partners S.A. 2,923 3,987 36.40
2018-08-14 13F-HR GOLDMAN SACHS GROUP INC 1,814 2,463 35.78
2018-08-14 13F-HR Wellington Management Group LLP 14,721 695 -95.28
2018-08-13 13F-HR Advisor Group, Inc. 4 8 100.00
2018-08-14 13F-HR CREDIT SUISSE AG/ 439 993 126.20
2018-08-13 13F-HR Oz Management LP 62,135 123,208 98.29
2018-08-14 13F-HR ARROWGRASS CAPITAL PARTNERS (US) LP 4,319 38,373 788.47
2018-07-20 13F-HR North Star Investment Management Corp. 1,000 1,000 0.00 1 2 100.00
2018-08-09 13F-HR SHENKMAN CAPITAL MANAGEMENT INC 4,944 4,452 -9.95
2018-08-14 13F-HR Kohlberg Kravis Roberts & Co. L.P. 24,215 36,415 50.38
2018-08-14 13F-HR Man Group plc 293 9,956 3,297.95
2018-08-13 13F-HR Hudson Bay Capital Management LP 135,678 181,019 33.42
2018-08-10 13F-HR GABELLI SECURITIES, INC. 219 298 36.07
2018-08-14 13F-HR CNH PARTNERS LLC 95,570 169,347 77.20
2018-07-05 13F-HR Verde Servicos Internacionais S.A. 30,000 0 -100.00 4,403 0 -100.00
2018-08-15 13F-HR JANE STREET GROUP, LLC 700,000 625,000 -10.71 1,026 1,266 23.39
2018-08-13 13F-HR CAMDEN ASSET MANAGEMENT L P /CA 46,135 82,491 78.80
2018-08-06 13F-HR MACKAY SHIELDS LLC 1,818 2,604 43.23
2018-08-10 13F-HR GABELLI FUNDS LLC 2,553 2,485 -2.66
2018-08-14 13F-HR Elliott Management Corporation 5,000,000 9,945
2018-08-13 13F-HR PALISADE CAPITAL MANAGEMENT LLC/NJ 4,988 6,770 35.73
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 3,543 19,864 460.65
2018-08-09 13F-HR BlackRock Inc. 2,341 2,135 -8.80
2018-08-10 13F-HR ONTARIO TEACHERS PENSION PLAN BOARD 8,795 15,901 80.80
2018-08-17 13F-HR/A NOMURA HOLDINGS INC 0 0
2018-08-14 13F-HR THRIVENT FINANCIAL FOR LUTHERANS 10,000,000 12,000,000 20.00 14,633 23,837 62.90
2018-07-31 13F-HR Front Row Advisors Llc 1,000 1,000 0.00 1 2 100.00
2018-08-14 13F-HR WOLVERINE ASSET MANAGEMENT LLC 93,042 134,445 44.50
2018-08-14 13F-HR MORGAN STANLEY 4,345 30 -99.31
2018-08-10 13F-HR Opera Trading Capital 26,325 36,794 39.77
2018-07-17 13F-HR CALAMOS WEALTH MANAGEMENT LLC 103 139 34.95
2018-08-10 13F-HR Mint Tower Capital Management B.V. 25,652 29,938 16.71
2018-08-06 13F-HR Bank of New York Mellon Corp 754,000 750,000 -0.53 1,106 1,517 37.16
2018-08-13 13F-HR Granite Point Capital Management, L.P. 732 993 35.66
2018-08-14 13F-HR STEELHEAD PARTNERS LLC 23,450 39,765 69.57
2018-08-14 13F-HR Magnetar Financial LLC 52,048 74,652 43.43
2018-08-14 13F-HR Point72 Asset Management, L.P. 1,493
2018-08-13 13F-HR AMP Capital Investors Ltd 175,000 0 -100.00 252 0 -100.00
2018-08-14 13F-HR CSS LLC/IL 12,606 13,944 10.61
2018-08-14 13F-HR Invesco Ltd. 7,317 9,932 35.74
2016-11-14 13F-HR EDMOND DE ROTHSCHILD ASSET MANAGEMENT (FRANCE) 4,915
2018-08-14 13F-HR JP Morgan Chase & Co 5,581 14,678 163.00
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 389 3,871 895.12
2018-08-14 13F-HR Graham Capital Management, L.P. 40,000,000 58,675 79,651 35.75
2018-08-14 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 4,983 4,847 -2.73
2018-08-14 13F-HR LORD, ABBETT & CO. LLC 6,277 16,140 157.13
2018-08-14 13F-HR STATE STREET CORP 25,975,000 26,875,000 3.46 37,894 53,575 41.38
2018-08-14 13F-HR DEUTSCHE BANK AG\ 6,804 10,837 59.27
2018-08-14 13F-HR UBS Group AG 4 6 50.00
2017-02-10 13F-HR BlackRock Advisors LLC 169 259 53.25
2018-08-14 13F-HR AMERIPRISE FINANCIAL INC 3,814 5,165 35.42
2018-08-07 13F-HR SG Americas Securities, LLC 1,403 14,907 962.51
2018-07-25 13F-HR BNP PARIBAS ARBITRAGE, SA 29,851,320 41,042,790 37.49

Related Articles

REPH: Recro Pharma Analysis and Research Report

20h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

20h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

21h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 007903BD8